本帖最后由 老马 于 2012-1-13 21:20 编辑
5 D0 p/ y6 C. B# G
" _; u8 Y1 s/ n+ }( O0 O) C7 Q爱必妥和阿瓦斯丁的比较
; {+ V* @6 w9 E6 G2 y( A7 R( `
( N T% \7 }7 u" C- \+ s8 Zhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 B* B5 I" `4 K( `3 b4 q
9 N4 A: Z7 `" t) l; R" S7 q0 N* _
0 B5 M# N0 L6 Q5 v- Z( Ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 T3 m4 M$ T* {% J% |==================================================
* p. f U. r! W2 u3 M. eOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)6 d# y5 l" ^8 m* N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; N: V" j# F5 h4 _+ D% fResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" O( ]: g" S w1 _0 Z! b
|